Chairman Jin Yang-gon Purchases 22,000 Shares of HLB Pep on the Open Market

Five Purchases Made Between August 12 and 19
Expanding Peptide API, CDMO, and New Drug Development Businesses

Jin Yang-gon, Chairman of HLB Group, purchased 22,000 shares of HLB Pep on the open market.

HLB Pep announced on August 20 that Chairman Jin had purchased a total of 22,000 shares of the company on the open market, making five separate transactions between August 12 and August 19.

HLBpep New Logo. HLBpep

Since the start of this year, Chairman Jin has conducted 51 open market purchases of shares in group affiliates, including HLB Pep, HLB Innovation, HLB Panagen, HLB Therapeutics, HLB Genex, and HLB BioStep. The total number of affiliate shares he has accumulated through these purchases now exceeds 1 million shares this year.

HLB Pep is expanding its portfolio of peptide active pharmaceutical ingredients (API) and broadening its business scope into global CDMO operations and new drug development.

The company is also strengthening its global CDMO business foundation centered around the Osong plant by advancing its manufacturing facilities and quality control systems, as well as enhancing its large-scale synthesis and high-level purification capabilities.

Recently, HLB Pep completed registration of vasopressin API—an antidiuretic hormone treatment—on the U.S. Food and Drug Administration (FDA) Drug Master File (DMF) list. The company also signed a CDMO agreement with a Japanese peptide specialist firm for the development and production of functional peptides.

An HLB Pep representative stated, "In line with the growth of the global peptide market, we will strengthen the competitiveness of our API and CDMO businesses and expand into new areas such as drug development to further enhance corporate value."

This content was produced with the assistance of AI translation services.